View cart/Checkout   Cart is empty   Allergy   Anti Depressant   Antibiotics   Anxiety   Arthritis (Rheumatics)   Asthma   Birth Control   Blood Pressure   Cardiovascular   Cholesterol   Contraceptive   Dermatitis   Diabetes   Diuretics   Gastroenterology   Influenza   Men's Health   Menopause   Migraine   Muscle Relaxant   Pain Relief   Parkinson's   Sleep & Insomnia   Weight Loss

Drugs by alphabet:      A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  Approved Rx Valium 5 mg Roche $ 155.00 add to cart Gelonida Pfizer (Paracetamol 500mg/30mg Codeine) $ 265.00 add to cart Xanax (Tafil) 0.5mg $ 187.00 add to cart Diazepam Ratiopharm 5 mg $ 142.00 add to cart

Diabetes Remission In Obese Patients More Likely With Weight Loss Surgery
Gastric banding surgery appeared to be more effective than conventional weight loss and diabetes control at helping obese patients with type 2 diabetes lose weight and achieve remission of diabetes, revealed the results of a preliminary study by researchers in Australia. More: continued here
Diabetes Remission In Obese Patients More Likely With Weight Loss Surgery...

Fda panel wants extra warnings on glaxo asthma drugs advair, serevent
GlaxoSmithKline's best-selling drug Advair, manufactured in part at a plant in Zebulon, may get new warnings on its label highlighting the drug's risk for children. (GSK) (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Fda panel wants extra warnings on glaxo asthma drugs advair, serevent...

Some Anemia Treatment Agents Increase Risk Of Blood Clots And Death In Cancer Patients
Using erythropoiesis-stimulating agents (ESAs) in thetreatment of anemia increases the risk of venous thromboembolism (VTE)and death among cancer patients, according to an article in theFebruary 27, 2008 issue of JAMA.ESAs are a class of drugs that promote red blood cell production in thebody. The ESAs erythropoietin and darbepoetin are
Some Anemia Treatment Agents Increase Risk Of Blood Clots And Death In Cancer Patients...

European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
Implementation of the Physical Agents (Electromagnetic Fields) Directive 2004/40/EC in all Member States could effectively halt the use of magnetic resonance imaging (MRI), an important tool in cancer diagnosis, treatment, and research, a scientist told a press conference at the European Cancer Conference (ECCO 14) (Monday September
European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer...

Rheumatology clinical exam videos
Rheumatology clinical exam videosRheumatology clinical exam videos QUOTE Rheumatology videos - milking effusion - Assessment of Medial Joint Line Tenderness - McMurray’s Test - Medial Collateral Ligament Testing - Lateral Collateral Ligament Testing … The association of the PTPN22 620W polymorphism with Behcet’s diseaseAnnals of Rheumatic Diseases Baranathan,
Rheumatology clinical exam videos...

Rotarix, An Oral Rotavirus Vaccine, Approved By The FDA
The FDA (Food and Drug Administration, USA) has approved Rotarix, an oral vaccine for the prevention of rotavirus - an infection in children and infants which causes vomiting and diarrhea (gastroenteritis). The vaccine, which is presented in liquid form, is given in two doses to infants aged 6
Rotarix, An Oral Rotavirus Vaccine, Approved By The FDA...

Additional Influenza Vaccine Approved For Upcoming Influenza Season - Approval Increases Available Doses To Record Level
The U.S. Food and Drug Administration approved Afluria, an additional seasonal influenza vaccine for the immunization of people ages 18 and older.Afluria is intended to protect adults from influenza type A and type B flu viruses. Influenza is a contagious respiratory illness that can cause annual
Additional Influenza Vaccine Approved For Upcoming Influenza Season - Approval Increases Available Doses To Record Level...

EVICEL(TM) Fibrin Sealant (Human) Approved For General Hemostasis In Surgery
ETHICON, INC. announced that the U.S. Food and Drug Administration has granted an expanded indication for EVICEL(TM) Fibrin Sealant (Human). The product is the first fibrin sealant to be indicated as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical
EVICEL(TM) Fibrin Sealant (Human) Approved For General Hemostasis In Surgery...

Artisan Pharma’s Lead Product, ART-123, Approved In Japan
Artisan Pharma, Inc. announced that the Japanese Pharmaceutical and Medical Device Agency approved Artisan’s lead drug, ART-123 (human, soluble, recombinant thrombomodulin), on January 25, 2008 for the treatment of disseminated intravascular coagulation (”DIC”) in Japan. The approval of ART-123, which was received by Artisan’s partner and licensor of
Artisan Pharma’s Lead Product, ART-123, Approved In Japan...